Journal of the Society for Cardiovascular Angiography & Interventions
Aligning Time Zero When Evaluating SGLT2 Inhibitors After TAVR
By Muiz Khan Tareen and Sidrat ul Muntaha Lone.
Abstract
We read with interest the study by Hanif et al evaluating sodium-glucose cotransporter-2 inhibitor (SGLT2i) use after transcatheter aortic valve replacement (TAVR) in patients with diabetes.1 In a large multinational electronic health record cohort, SGLT2i exposure was associated with lower risks of major adverse cardiovascular events, cardiovascular mortality, heart failure (HF) exacerbation, stroke, and renal events. These findings are clinically relevant and complement emerging randomized evidence supporting SGLT2 inhibition after TAVR.
Keywords
- Cardiac Valve Diseases and Treatments
- SGLT2 inhibitors
- transcatheter aortic valve implantation
- post-TAVR outcomes
- timing of drug initiation
- Open access
Source
Published in Journal of the Society for Cardiovascular Angiography & Interventions. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.